About: Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $17.39 (-4.19%)
JANX NASDAQ Janux Therapeutics Inc
Janux Therapeutics Inc share price
JANX price activity
Last Price
$18.150
Change (24hr)
-0.24 USD (-1.31%)
Volume
802.48K
Volume (4w avg)
-
Open
$18.52
Day Range
$18.15 - $18.52
Previous Close
$18.39
Last Trade
12 Oct, 8:00 pm GMT+0
Delayed
12 Oct, 8:00 pm GMT+0
JANX price performance
Delayed
12 Oct, 8:00 pm GMT+0
JANX Market Signals